CRVS Corvus Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why CRVS matters now
Corvus Pharmaceuticals, Inc. (CRVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.09 with -2.56% on the session and $1.18B in market capitalization; recent performance reads 1-month +3.57% and YTD +54.68%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.7M, and EPS of $-0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.5%.
The latest indexable market news headline is "Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $31.00; recent insider activity includes van den Broek Richard filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.45
P/S
0.00
EV/EBITDA
-22.76
DCF Value
$0.02
FCF Yield
-3.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.9%
ROA
-17.4%
ROIC
-19.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.7M | $-0.15 |
| Q4 2025 | $0.00 | $-12.3M | $-0.18 |
| FY 2025 | $0.00 | $-15.3M | $-0.53 |
| Q3 2025 | $0.00 | $-10.2M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.17
Target (Median)
$31.00
Target Range
$27.00 - $42.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.